Medifast (MED) Accounts Payables (2010 - 2026)

Medifast's Accounts Payables history runs 17 years deep, the most recent figure standing at $38.3 million for Q1 2026.

• Quarterly Accounts Payables fell 26.15% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.3 million (down 26.15% YoY) and the FY2025 annual result came in at $38.4 million, down 32.1% from the prior year.
• Accounts Payables was $38.3 million for Q1 2026 at Medifast, roughly flat from $38.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $174.4 million in Q1 2022 and bottomed at $38.3 million in Q1 2026.
• A 5-year average of $87.8 million and a median of $71.2 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables gained 23.45% — and 2025, when it slumped 41.78%.
• Medifast's Accounts Payables stood at $134.7 million in 2022, then plunged by 35.84% to $86.4 million in 2023, then tumbled by 34.62% to $56.5 million in 2024, then sank by 32.1% to $38.4 million in 2025, then decreased by 0.25% to $38.3 million in 2026.
• Business Quant data shows MED's Accounts Payables at $38.3 million in Q1 2026, $38.4 million in Q4 2025, and $41.2 million in Q3 2025.